Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023

Eligible patients will receive full MS patient support program through Cycle Vita™

Boston, Massachusetts and San Jose, California – November 1, 2022 – Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce its intention to commercialize TASCENSO ODT^® (fingolimod) in the US multiple sclerosis (MS) market in Q1 2023.

The launch of TASCENSO ODT aims to address the withdrawal of the Gilenya^®(fingolimod) capsules patient support program (Go Program^®) on March 31, 20231. Eligible patients* prescribed TASCENSO ODT will have access to patient support from Cycle Vita™, Cycle’s dedicated, in-house patient support hub, designed specifically with the needs of patients in mind.

The launch follows a partnership between Cycle and Handa Neuroscience, LLC (Handa), the developer of TASCENSO ODT, to commercialize both the 0.25mg and 0.5mg strengths in the US. The patient support provided through Cycle Vita will ensure that eligible patients are able to continue on, or initiate, fingolimod treatment with TASCENSO ODT while receiving access to patient support such as appropriate insurance navigation, financial assistance, first-dose observation and baseline assessments beyond March 31, 2023. [read more]

CMSC Disclaimer

The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.